版本:
中国

BRIEF-Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call

April 25 Biogen Inc

* Biogen says "we are working to add more assetts to our pipeline": Conf Call

* Biogen says "underlying tecfidera demand in the U.S. remains stable", and co is well poised to compete against rivals: Conf Call

* Biogen says it has maintained global MS market share, despite competition: Conf Call

* Biogen says underlying Spinraza demand in U.S. is robust, and numbers increasingly every week: Conf Call

* Biogen says 165 plans now cover Spinraza; of all insurance plans, atleast 75 percent cover Spinraza: Conf Call

* Biogen Exec says it will be closely watching the performance of roche's new MS drug Ocrevus; Biogen has a royalty deal with Roche for the drug

* Biogen CEO sees low single digit growth in MS market in remainder of 2017: Conf Call

* Biogen CFO says co will not comment on pricing plans for Biogen's MS drugs: Conf Call

* Biogen Exec says "we don't know ultimatley what the long-term durability of Spinraza is...but data so far has been enocuraging": Conf Call

* Biogen CFO says Roche's MS drug Ocrevus has negatively impacted Tysabri more than other Biogen drugs: Conf Call

* Biogen CFO says its hard to tell the kinetics of Spinraza performance, but expects adoption to ramp up going forward: Conf Call Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐